Quarterly report [Sections 13 or 15(d)]

SIGNIFICANT ACCOUNTING POLICIES (Details 2)

v3.25.3
SIGNIFICANT ACCOUNTING POLICIES (Details 2) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
SIGNIFICANT ACCOUNTING POLICIES        
Net loss Attributable to BioCorRX inc. $ (1,917,873) $ (1,487,387) $ (3,992,701) $ (3,941,509)
Net loss per common share, basic and diluted $ (0.11) $ (0.14) $ (0.24) $ (0.41)
Weighted average number of common shares outstanding, basic and diluted 18,162,783 10,908,291 16,901,306 9,712,939